ENGAGING PATIENTS IN A CONVERSATION ABOUT NALOXONE WB4665

PROGRAM DESCRIPTION: This enduring activity is designed to increase knowledge and change competency of clinicians on identifying patients at increased risk for opioid overdose and practices and strategies for offering naloxone.

OBJECTIVES:

At the conclusion of the session, the participant should be able to:

- 1. Identify the key points to share with patients about risk of overdose when using opioids.
- 2. Identify how interprofessional care coordination to support offering of naloxone can reduce the risk of opioid overdose.

FACULTY/ CREDENTIALS:

Christina A. Mikosz, MD, MPH, Lead Medical Officer, Division of Overdose Prevention, National Center for Injury Prevention and Control (NCIPC), Centers for Disease Control and Prevention

Molly Dowling, MPH, Health Communications Specialist, Division of Overdose Prevention, National Center for Injury Prevention and Control (NCIPC), Centers for Disease Control and Prevention

ORIGINATION DATE:	07/28/2023
EXPIRATION DATE:	07/28/2025

URL: https://www.cdc.gov/opioids/naloxone/training/talkingabout-naloxone.htmll HARDWARE/SOFTWARE: Computer Hardware; Internet Connection; Browser None MATERIALS: TARGET AUDIENCE: Physicians, Registered Nurses PREREQUISITES: None FORMAT: This activity is Web-based. **CONTACT INFORMATION:** Division of Overdose Prevention, National Center for Injury Prevention and Control 800-232-4636

ACCREDITATION STATEMENTS:



In support of improving patient care, The Centers for Disease Control and Prevention is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

CME: The Centers for Disease Control and Prevention designates this **enduring** activity for a maximum of **0.5** AMA PRA Category 1 Credits[™]. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CNE: The Centers for Disease Control and Prevention designates this activity for **0.5** nursing contact hours.

DISCLOSURE: In compliance with continuing education requirements, all planners and presenters must disclose all financial relationships, in any amount, with ineligible companies during the previous 24 months as well as any use of unlabeled product(s) or products under investigational use.

CDC, our planners, and content experts wish to disclose they have no financial relationship(s) with ineligible companies whose primary business is producing, marketing, selling, reselling, or distributing healthcare products used by or on patients.

Content will not include any discussion of the unlabeled use of a product or a product under investigational use.

CDC did not accept financial or in-kind support from ineligible companies for this continuing education activity.

Instructions for Obtaining Continuing Education (CE)

To receive continuing education (CE) for **WB4665 Engaging Patients in a Conversation about Naloxone** please visit <u>TCEO</u> and follow these <u>9 Simple Steps</u> before **07/28/2025**.

Complete the activity Complete the Evaluation at <u>www.cdc.gov/GetCE</u> Pass the posttest at **80%** at <u>www.cdc.gov/GetCE</u>

FEES: No fees are charged for CDC's CE activities.